Revenue segments as reported by the company.

Protein Sciences

Diagnostics and Genomics

lntersegment

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bio-Techne

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded in 1976 and is headquartered in Minneapolis, MN.

Earnings data Q3 2024

Bio-Techne Corp reports steady Q3 revenue growth amidst China challenges

Bio-Techne Corp reported steady Q3 revenue growth despite challenges in China and temporary headwinds. The company is focused on driving growth in strategic platforms and expanding key franchises. Succession planning and margin improvement are key areas of focus for future growth.

Bio-Techne reports 5% organic growth, anticipates margin dilution

Bio-Techne reported positive organic growth but faces challenges from the 'COVID hangover' and uncertainties in the macro environment, particularly in China. The company is confident in its M&A strategy and the potential of recent acquisitions, while also focusing on automating and enhancing their discovery platform for more efficient translational processes.

Bio-Techne reports resilient Q3 performance amidst biotech funding challenges

Bio-Techne's Q3 performance showcased resilience with organic growth, particularly in Europe. The company faces challenges from biotech funding constraints and economic headwinds in China but remains optimistic about future growth. The focus on core growth platforms and continued investment in growth opportunities position Bio-Techne for long-term success.

Bio-Techne faces Q2 headwinds but anticipates return to growth

Bio-Techne's Q2 performance was impacted by biopharma funding constraints, destocking, and economic challenges in China. Despite this, the company remains confident in its strategic growth pillars and the potential for a return to positive organic growth in 4Q. The company's focus on academic markets, quality antibodies, and M&A for portfolio enhancement reflects its proactive approach to addressing challenges and capitalizing on opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Genomics segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.

Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Techne (TECH) to Report a Decline in Earnings: What to Look Out for

Bio-Techne enforces intellectual property for gold standard RNAscope® ISH technology in spatial biology research and clinical applications. MINNEAPOLIS , April 23, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced that it has taken legal action in the Unified Patent Court in Europe to halt the infringement of its patented RNAscope® ISH technology by Molecular Instruments, Inc. Bio-Techne, under its Advanced Cell Diagnostics (ACD) brand, owns patents covering numerous features of its RNAscope technology.

BIO-TECHNE FILES PATENT INFRINGEMENT LAWSUIT AGAINST MOLECULAR INSTRUMENTS

MINNEAPOLIS , April 10, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 1, 2024, at 8:00 a.m. CDT to review third quarter fiscal 2024 financial results.

BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 1, 2024, TO ANNOUNCE THIRD QUARTER FISCAL 2024 FINANCIAL RESULTS

Advanced Cell Diagnostics (ACD) achieves significant global customer adoption milestone MINNEAPOLIS , April 8, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD), part of Bio-Techne's Spatial Biology Division, has surpassed 10,000 peer-reviewed publications referencing the use and application of RNAscope™ ISH technology. Over 50% of these publications were released in the past 3 years, as increasing global customer awareness and expanded market adoption solidify ACD's leadership in spatial biology applications.

BIO-TECHNE SURPASSES 10,000 PEER-REVIEWED PUBLICATIONS CITING RNAscope TECHNOLOGY

Bio-Techne is a life science tools and services company focused on the development and sale of reagents and consumables for life science research. The company's focus on the stable and lucrative life science research market has led to above-average growth and profitability compared to diagnostic companies. Bio-Techne has exhibited strong financial performance, with high profit margins and low leverage, making it a top performer among its peers.

Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence

MINNEAPOLIS, April 3, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced it will showcase its portfolio of solutions to advance cancer research from target discovery to cell therapy development at the upcoming annual meeting of the American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, California. Bio-Techne will showcase its solutions at booth #541, featuring our market-leading portfolio of high-grade life science reagents, immunoassays, automated proteomic analytical instruments, and multiomics solutions that are enabling new drug discovery research, accelerating immune cell therapy, and supporting the development of better diagnostic tools.

BIO-TECHNE TO PRESENT AT THE 2024 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) CONFERENCE

MINNEAPOLIS , April 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced that its R&D Systems brand has been named "ELISA Kit Supplier of the Year" in CiteAb's prestigious annual industry awards. Additionally, Advanced Cell Diagnostics (ACD), part of Bio-Techne's Spatial Biology Division, was named winner of "The Innovation Award" in recognition of its RNAscope™ ISH technology and its role in helping to advance scientific discovery.

BIO-TECHNE RECEIVES CiteAb'S ELISA KIT SUPPLIER OF THE YEAR AND SPATIAL BIOLOGY INNOVATION AWARDS

MINNEAPOLIS, March 28, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is pleased to announce that Lunaphore, part of Bio-Techne's Spatial Biology Division, is partnering with Nikon Instruments Inc. (Nikon) to expand access to spatial biology services with the COMET™ platform for US-based biotech, pharma, and academic customers. Lunaphore's flagship COMET technology is the only fully-automated,  high-throughput, hyperplex platform with superior tissue profiling capabilities, which performs protein detection with standard, non-conjugated antibodies.

BIO-TECHNE AND NIKON INSTRUMENTS INC. ANNOUNCE PARTNERSHIP TO EXPAND ACCESS TO INNOVATIVE SPATIAL BIOLOGY SERVICES

CRISPR Therapeutics

Moderna

Last year was a tough one for biotech stocks. The Securities and Exchange Commission reported 41 bankruptcies following the Fed's interest rate hiking cycle, making it difficult to finance debt.

3 Biotech Stocks That Could Be Multibaggers in the Making: March Edition

GlaxoSmithKline

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of GSK (GSK) and Techne (TECH). But which of these two stocks is more attractive to value investors?

GSK or TECH: Which Is the Better Value Stock Right Now?

The QuantideX® qPCR BCR-ABL IS Kit is now compliant with the latest diagnostic regulations in Europe MINNEAPOLIS , March 22, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, part of Bio-Techne's Molecular Diagnostics Division, has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation (IVDR) for its QuantideX® qPCR BCR-ABL IS Kit. Previously, the kit was CE-IVD marked for sale in the EU in compliance with the In Vitro Diagnostic Directive (IVDD), which has now been replaced by the IVDR.

BIO-TECHNE RECEIVES EUROPEAN IVDR CERTIFICATION FOR DIAGNOSTIC TEST TO MONITOR CHRONIC MYELOID LEUKEMIA

Centessa Pharmaceuticals PLC

Catalyst Pharmaceuticals

Cytokinetics

Iovance Biotherapeutics

Madrigal Pharmaceuticals

Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.

7 Biotech Stocks Ready to Ride the Sector's Resurgence

MINNEAPOLIS, March 12, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Will Geist, President, Protein Sciences Segment, will present at the KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024, at 9:45 a.m. EDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

BIO-TECHNE TO PRESENT AT THE KEYBANC LIFE SCIENCES & MEDTECH INVESTOR FORUM

MINNEAPOLIS , March 6, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13, 2024, at 8:30 a.m. EDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

BIO-TECHNE TO PRESENT AT THE BARCLAYS 26th ANNUAL GLOBAL HEALTHCARE CONFERENCE

Harmony Biosciences Holdings

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Techne (TECH). But which of these two stocks is more attractive to value investors?

HRMY vs. TECH: Which Stock Is the Better Value Option?

Exelixis

Pfizer

When searching for the best biotech stocks to buy, investors may be initially off-put by the industry's volatile nature. However, the sector is still stable and capable of continuously providing growth over time.

The 3 Best Biotech Stocks to Buy in February 2024

Bio-Techne Corporation (TECH) Q2 2024 Earnings Call Transcript

Although the revenue and EPS for Techne (TECH) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Here's What Key Metrics Tell Us About Techne (TECH) Q2 Earnings

Techne (TECH) came out with quarterly earnings of $0.40 per share, missing the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.47 per share a year ago.

Techne (TECH) Q2 Earnings and Revenues Lag Estimates

MINNEAPOLIS , Feb. 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ended December 31, 2023. Second Quarter FY2024 Highlights Second quarter organic revenue declined by 2% (0% reported) to $272.6 million.

BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2024 RESULTS

MINNEAPOLIS , Feb. 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2023. The quarterly dividend will be payable February 26, 2024, to all common shareholders of record on February 12, 2024.

BIO-TECHNE DECLARES DIVIDEND

Beyond analysts' top -and-bottom-line estimates for Techne (TECH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

What Analyst Projections for Key Metrics Reveal About Techne (TECH) Q2 Earnings

Advanced Cell Diagnostics (ACD), a Bio-Techne spatial biology brand, achieves technical breakthrough enabling protease-free, same-slide detection of protein and RNA biomarkers using industry-leading RNAscope™ technology. MINNEAPOLIS , Jan. 29, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD), a Bio-Techne spatial biology brand, has set a new standard with the development of a next-generation, protease-free RNAscope spatial multiomics workflow.

BIO-TECHNE'S ADVANCED CELL DIAGNOSTICS (ACD) SETS NEW STANDARD IN SPATIAL BIOLOGY WITH PROTEASE-FREE RNASCOPE MULTIOMICS

MINNEAPOLIS , Jan. 25, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its spatial biology brands, Lunaphore and Advanced Cell Diagnostics (ACD), will launch the first fully automated spatial multiomics workflow with same-section hyperplex detection of RNA and protein biomarkers. This state-of-the-art solution revolutionizes the field of predictive biomarker research and drug development.

LUNAPHORE AND ACD REVOLUTIONIZE SPATIAL BIOLOGY RESEARCH WITH THE LAUNCH OF THE FIRST FULLY AUTOMATED, SAME-SECTION, HYPERPLEX MULTIOMICS APPLICATION

MINNEAPOLIS , Jan. 24, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) had the honor of welcoming presentations from leading scientists from two major biopharmaceutical companies, Pfizer and Sanofi, at the WCBP conference held in Washington D.C. The focus of these presentations was on the transformative impact of Bio-Techne's MauriceFlex™ system on their biotherapeutic development processes.

News for Bio-Techne Stock (TECH)